TT-4 as a Single Agent in Subjects With Advanced Selected Solid Tumors
Status:
Not yet recruiting
Trial end date:
2023-09-30
Target enrollment:
Participant gender:
Summary
The purpose of this study is to evaluate the safety and tolerability of orally administered
TT-4 in subjects with advanced selected solid tumors. The dose escalation portion of the
study will determine the maximum tolerated dose (MTD) or recommended phase 2 dose (RP2D) of
TT-4.